Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Quantum BioPharma (NASDAQ:QNTM) has signed an agreement with Ingenu CRO Pty to conduct a clinical study observing disease progression in patients with primary progressive multiple sclerosis. The study, announced on September 9, 2024, will be carried out through Quantum's subsidiary, HUGE Biopharma Australia Pty This observational study is a important step towards initiating a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS), advancing Quantum's multiple sclerosis research program. Dr. Andrzej Chruscinski, VP of Scientific and Clinical Affairs at Quantum Biopharma, expressed enthusiasm about the collaboration, highlighting its importance in progressing their MS research efforts.
Quantum BioPharma (NASDAQ:QNTM) ha firmato un accordo con Ingenu CRO Pty per condurre uno studio clinico volto a osservare la progressione della malattia nei pazienti con sclerosi multipla primariamente progressiva. Lo studio, annunciato il 9 settembre 2024, sarà realizzato tramite la controllata di Quantum, HUGE Biopharma Australia Pty. Questo studio osservazionale rappresenta un passo importante verso l'avvio di un futuro studio clinico di fase 2 con Lucid-21-302 (Lucid-MS), facendo progredire il programma di ricerca della sclerosi multipla di Quantum. Il Dr. Andrzej Chruscinski, VP delle Attività Scientifiche e Cliniche di Quantum Biopharma, ha espresso entusiasmo per la collaborazione, sottolineando la sua importanza nel far progredire i loro sforzi di ricerca sulla SM.
Quantum BioPharma (NASDAQ:QNTM) ha firmado un acuerdo con Ingenu CRO Pty para llevar a cabo un estudio clínico que observe la progresión de la enfermedad en pacientes con esclerosis múltiple primaria progresiva. El estudio, anunciado el 9 de septiembre de 2024, se realizará a través de la filial de Quantum, HUGE Biopharma Australia Pty. Este estudio observacional es un paso importante hacia el inicio de un futuro ensayo clínico de fase 2 con Lucid-21-302 (Lucid-MS), avanzando en el programa de investigación sobre la esclerosis múltiple de Quantum. El Dr. Andrzej Chruscinski, VP de Asuntos Científicos y Clínicos en Quantum Biopharma, expresó su entusiasmo por la colaboración, destacando su importancia en el avance de sus esfuerzos de investigación sobre la EM.
Quantum BioPharma (NASDAQ:QNTM)은 Ingenu CRO Pty와 1차 진행성 다발성 경화증 환자에서 질병 진행을 관찰하는 임상 연구를 수행하기 위한 협약을 체결했습니다. 2024년 9월 9일에 발표된 이 연구는 Quantum의 자회사인 HUGE Biopharma Australia Pty를 통해 수행됩니다. 이 관찰 연구는 Lucid-21-302 (Lucid-MS)와 함께하는 향후 2상 임상 시험을 시작하는 중요한 단계로, Quantum의 다발성 경화증 연구 프로그램을 발전시키고 있습니다. Quantum BioPharma의 과학 및 임상 업무 VP인 Andrzej Chruscinski 박사는 협력에 대한 열정을 표명하며, 그들의 MS 연구 노력을 진전시키는 데 있어 중요성을 강조했습니다.
Quantum BioPharma (NASDAQ:QNTM) a signé un accord avec Ingenu CRO Pty pour réaliser une étude clinique observant la progression de la maladie chez des patients atteints de sclérose en plaques primaire progressive. L'étude, annoncée le 9 septembre 2024, sera menée par l'intermédiaire de la filiale de Quantum, HUGE Biopharma Australia Pty. Cette étude observationnelle représente une étape importante vers le lancement d'un futur essai clinique de phase 2 avec Lucid-21-302 (Lucid-MS), faisant progresser le programme de recherche de Quantum sur la sclérose en plaques. Le Dr. Andrzej Chruscinski, VP des affaires scientifiques et cliniques chez Quantum Biopharma, a exprimé son enthousiasme pour la collaboration, soulignant son importance dans l'avancement de leurs efforts de recherche sur la SP.
Quantum BioPharma (NASDAQ:QNTM) hat eine Vereinbarung mit Ingenu CRO Pty unterzeichnet, um eine klinische Studie zur Beobachtung des Krankheitsverlaufs bei Patienten mit primär progredienter Multipler Sklerose durchzuführen. Die Studie, die am 9. September 2024 angekündigt wurde, wird über die Tochtergesellschaft von Quantum, HUGE Biopharma Australia Pty, durchgeführt. Diese Beobachtungsstudie ist ein wichtiger Schritt zur Einleitung einer zukünftigen Phase-2-Studie mit Lucid-21-302 (Lucid-MS) und fördert das Forschungsprogramm von Quantum zur Multiplen Sklerose. Dr. Andrzej Chruscinski, VP für Wissenschaftliche und Klinische Angelegenheiten bei Quantum Biopharma, äußerte Begeisterung über die Zusammenarbeit und hob deren Bedeutung für den Fortschritt ihrer MS-Forschung hervor.
- Agreement signed with Ingenu CRO to conduct a clinical study on primary progressive multiple sclerosis
- Study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS)
- Advances Quantum BioPharma's multiple sclerosis research program
- None.
Insights
This agreement marks a pivotal step for Quantum BioPharma in advancing their multiple sclerosis (MS) research program. The observational study with Ingenu CRO is important for quantifying disease progression in primary progressive MS patients, which will inform the design of their upcoming Phase 2 clinical trial for Lucid-21-302 (Lucid-MS). This approach demonstrates a methodical and data-driven strategy in drug development.
The focus on primary progressive MS is particularly noteworthy, as it's a form of MS with treatment options and a high unmet medical need. By studying disease progression, Quantum BioPharma can potentially optimize their Phase 2 trial design, increasing the chances of demonstrating efficacy for Lucid-MS. This could position the company favorably in the competitive landscape of MS therapeutics.
While this news doesn't directly impact Quantum BioPharma's financials, it signals progress in their drug development pipeline, which is important for biotech valuations. The agreement with Ingenu CRO suggests the company is actively advancing towards a Phase 2 trial, a significant milestone that typically increases investor confidence.
However, it's important to note that this is still an early stage and multiple hurdles remain before potential commercialization. The MS market is highly competitive, with several established players. Investors should consider the long-term nature of drug development and the substantial costs associated with clinical trials. While positive, this news alone may not significantly impact the stock in the short term, but it contributes to the company's overall value proposition and potential for future growth.
TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).
"We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
Contact Information
Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
416-854-8884
SOURCE: Quantum Biopharma Ltd.
View the original press release on accesswire.com
FAQ
What is the purpose of Quantum BioPharma's new clinical study with Ingenu CRO?
When did Quantum BioPharma (QNTM) sign the agreement for the MS clinical study?
What is Lucid-21-302 in relation to Quantum BioPharma's research?
Which subsidiary of Quantum BioPharma (QNTM) is involved in the MS clinical study?
